Medtronic (NYSE:MDT) today said it would acquire insulin pen manufacturer Companion Medical for an undisclosed amount.
Companion Medical’s product portfolio includes the InPen FDA-cleared smart insulin pen system that is paired with an integrated diabetes management app on the market. It is designed to help calculate insulin doses, track active insulin and send reports to caregivers and is available in the U.S. by prescription only.
The InPen adds to Medtronic’s diabetes portfolio of the MiniMed insulin pump, Guardian CGM and more.
Get the full story on our sister site, Drug Delivery Business News.
